市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Adagene Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | 3.0 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.13 |
|
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 4.70% |
| 机构持股比例 | 33.39% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Moneta Group Investment Advisors Llc | 30 Jun 2026 | 200,000 |
| Mill Creek Capital Advisors, Llc | 31 Mar 2026 | 199,610 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| TAM MAN KIN | 2.97 | - | 2,000 | 5,940 |
| 累积净数量 | 2,000 | |||
| 累积净值 ($) | 5,940 | |||
| 累积平均购买 ($) | 2.97 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| TAM MAN KIN | 职员 | 23 Sep 2026 | 买 (+) | 2,000 | 2.97 | 5,940 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合